Tested positive again for COVID-19; COVID-19 treated with Paxlovid; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Tested positive again for COVID-19) and COVID-19 (COVID-19 treated with Paxlovid) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hypothyroidism, Hashimoto's disease, Anxiety and Allergy. Concomitant products included PARACETAMOL (TYLENOL), DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, EPHEDRINE SULFATE, ETHANOL, PARACETAMOL (NYQUIL), LEVOTHYROXINE SODIUM (UNITHROID), ESCITALOPRAM OXALATE (LEXAPRO) and VITAMINS NOS (VITAMINS) for an unknown indication.    On 29-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In May 2022, the patient experienced COVID-19 (COVID-19 treated with Paxlovid). On 19-May-2022, the patient experienced COVID-19 (Tested positive again for COVID-19). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 10-May-2022 to 15-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (Tested positive again for COVID-19) had not resolved and COVID-19 (COVID-19 treated with Paxlovid) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 19-May-2022, SARS-CoV-2 test: positive (Positive) Positive. On 21-May-2022, SARS-CoV-2 test: positive (Positive) Positive with very dark line right away.         The patient experienced symptoms like runny nose, slight sore throat, mild cough about 4 days after last Paxlovid dose, all same as when first diagnosed but in milder form. No treatment medication was reported by reporter. Device date was reported as 21-May-2022.  Company Comment: This is a spontaneous case concerning a 44-year-old female patient with no relevant medical history reported, who experienced the unexpected non-serious adverse event of special interest COVID-19 (reported as COVID-19 and COVID-19 recurrent), which occurred after receiving a dose of mRNA-1273 as the third dose of COVID-19 vaccine (no information disclosed on previous COVID-19 vaccinations). The initial infection of COVID-19 occurred approximately 6 month after the third dose, while the event COVID-19 recurrent occurred approximately 6 months and 21 days post-vaccination. Patient described that her first infection of COVID-19 had mild symptoms of runny nose, slight sore throat, and mild cough and was treated with Paxlovid for 6 days. Four days after, patient reported that the same milder symptoms reoccurred and was tested positive for COVID-19. Patient reported that the event COVID-19 recurrent was not resolved. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 44-year-old female patient with no relevant medical history reported, who experienced the unexpected non-serious adverse event of special interest COVID-19 (reported as COVID-19 and COVID-19 recurrent), which occurred after receiving a dose of mRNA-1273 as the third dose of COVID-19 vaccine (no information disclosed on previous COVID-19 vaccinations). The initial infection of COVID-19 occurred approximately 6 month after the third dose, while the event COVID-19 recurrent occurred approximately 6 months and 21 days post-vaccination. Patient described that her first infection of COVID-19 had mild symptoms of runny nose, slight sore throat, and mild cough and was treated with Paxlovid for 6 days. Four days after, patient reported that the same milder symptoms reoccurred and was tested positive for COVID-19. Patient reported that the event COVID-19 recurrent was not resolved. The benefit-risk relationship of mRNA-1273 is not affected by this report.